Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akesis Pharmaceuticals, a specialty pharmaceutical company, has appointed Carl LeBel, current president and COO, to the role of its president and CEO.
Subscribe to our email newsletter
Dr LeBel has served as president and COO since June 2008 and has been on Akesis’s board of directors since December 2007. The company has stated that the current chairman and CEO, Jay Lichter, will now assume the position of executive chairman of the board of directors.
Dr Lichter said: “Since joining Akesis, Carl’s leadership has been instrumental in expanding and advancing our AKP-020 diabetes program, and he has established key scientific, medical and regulatory advisor relationships for the organization.
“With his extensive product development experience in diabetes, obesity, and osteoporosis, he is the ideal leader to take the helm and further position Akesis for success as a specialty pharmaceutical company focused on metabolic diseases.”